Cerebrospinal Fluid HIV Escape from Antiretroviral Therapy

Current HIV/AIDS Reports

Volumn 12, Issue 2, 2015, Pages 280-288

  Ferretti, Francesca ^a   Gisslen, Magnus ^b   Cinque, Paola ^a   Price, Richard W ^c  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Brain; Central nervous system (CNS); Cerebrospinal fluid (CSF); Encephalitis; HIV; Treatment

Indexed keywords

ANTIRETROVIRUS AGENT;

BLOOD BRAIN BARRIER; CEREBROSPINAL FLUID; HIV INFECTIONS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; ISOLATION AND PURIFICATION; VIROLOGY;

ANTI-RETROVIRAL AGENTS; BLOOD-BRAIN BARRIER; CEREBROSPINAL FLUID; HIV; HIV INFECTIONS; HUMANS;

EID: 84937762971     PISSN: 15483568     EISSN: 15483576     Source Type: Journal    
DOI: 10.1007/s11904-015-0267-7     Document Type: Review

References (74)

1. Valcour V, Chalermchai T, Sailasuta N, Marovich M, Lerdlum S, Suttichom D, et al. Central nervous system viral invasion and inflammation during acute HIV infection. J Infect Dis. 2012;206(2):275–82. doi:10.1093/infdis/jis326.
2. Tambussi G, Gori A, Capiluppi B, Balotta C, Papagno L, Morandini B, et al. Neurological symptoms during primary human immunodeficiency virus (HIV) infection correlate with high levels of HIV RNA in cerebrospinal fluid. Clin Infect Dis Off Publ Infect Dis Soc Am. 2000;30(6):962–5. doi:10.1086/313810.
3. Enting RH, Prins JM, Jurriaans S, Brinkman K, Portegies P, Lange JM. Concentrations of human immunodeficiency virus type 1 (HIV-1) RNA in cerebrospinal fluid after antiretroviral treatment initiated during primary HIV-1 infection. Clin Infect Dis Off Publ Infect Dis Soc Am. 2001;32(7):1095–9. doi:10.1086/319602.
4. Conrad AJ, Schmid P, Syndulko K, Singer EJ, Nagra RM, Russell JJ, et al. Quantifying HIV-1 RNA using the polymerase chain reaction on cerebrospinal fluid and serum of seropositive individuals with and without neurologic abnormalities. J Acquir Immune Defic Syndr Hum Retrovirol Off Publ Int Retrovirol Assoc. 1995;10(4):425–35.
5. Chiodi F, Keys B, Albert J, Hagberg L, Lundeberg J, Uhlen M, et al. Human immunodeficiency virus type 1 is present in the cerebrospinal fluid of a majority of infected individuals. J Clin Microbiol. 1992;30(7):1768–71.
6. Cinque P, Vago L, Ceresa D, Mainini F, Terreni MR, Vagani A, et al. Cerebrospinal fluid HIV-1 RNA levels: correlation with HIV encephalitis. AIDS. 1998;12(4):389–94.
7. Staprans S, Marlowe N, Glidden D, Novakovic-Agopian T, Grant RM, Heyes M, et al. Time course of cerebrospinal fluid responses to antiretroviral therapy: evidence for variable compartmentalization of infection. AIDS. 1999;13(9):1051–61.
8. Yilmaz A, Svennerholm B, Hagberg L, Gisslen M. Cerebrospinal fluid viral loads reach less than 2 copies/ml in HIV-1-infected patients with effective antiretroviral therapy. Antivir Ther. 2006;11(7):833–7.
9. Robertson KR, Smurzynski M, Parsons TD, Wu K, Bosch RJ, Wu J, et al. The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS. 2007;21(14):1915–21. doi:10.1097/QAD.0b013e32828e4e27.
10. Sacktor N, Robertson K. Evolving clinical phenotypes in HIV-associated neurocognitive disorders. Curr Opin HIV AIDS. 2014;9(6):517–20. doi:10.1097/COH.0000000000000102.
11. Gisslen M, Fuchs D, Svennerholm B, Hagberg L. Cerebrospinal fluid viral load, intrathecal immunoactivation, and cerebrospinal fluid monocytic cell count in HIV-1 infection. J Acquir Immune Defic Syndr. 1999;21(4):271–6.
12. Spudich SS, Nilsson AC, Lollo ND, Liegler TJ, Petropoulos CJ, Deeks SG, et al. Cerebrospinal fluid HIV infection and pleocytosis: relation to systemic infection and antiretroviral treatment. BMC Infect Dis. 2005;5:98. doi:10.1186/1471-2334-5-98.
13. Stam AJ, Nijhuis M, van den Bergh WM, Wensing AM. Differential genotypic evolution of HIV-1 quasispecies in cerebrospinal fluid and plasma: a systematic review. AIDS Rev. 2013;15(3):152–61.
14. Price RW, Spudich S. Antiretroviral therapy and central nervous system HIV type 1 infection. J Infect Dis. 2008;197 Suppl 3:S294–306. doi:10.1086/533419.
15. Chaillon A, Gianella S, Wertheim JO, Richman DD, Mehta SR, Smith DM. HIV migration between blood and cerebrospinal fluid or semen over time. J Infect Dis. 2014;209(10):1642–52. doi:10.1093/infdis/jit678.
16. Karlsson U, Antonsson L, Ljungberg B, Medstrand P, Esbjornsson J, Jansson M, et al. Dual R3R5 tropism characterizes cerebrospinal fluid HIV-1 isolates from individuals with high cerebrospinal fluid viral load. AIDS. 2012;26(14):1739–44. doi:10.1097/QAD.0b013e3283560791.
17. Schnell G, Price RW, Swanstrom R, Spudich S. Compartmentalization and clonal amplification of HIV-1 variants in the cerebrospinal fluid during primary infection. J Virol. 2010;84(5):2395–407. doi:10.1128/JVI. 01863-09.
18. Maslin CL, Kedzierska K, Webster NL, Muller WA, Crowe SM. Transendothelial migration of monocytes: the underlying molecular mechanisms and consequences of HIV-1 infection. Curr HIV Res. 2005;3(4):303–17.
19. Nottet HS, Persidsky Y, Sasseville VG, Nukuna AN, Bock P, Zhai QH, et al. Mechanisms for the transendothelial migration of HIV-1-infected monocytes into brain. J Immunol. 1996;156(3):1284–95.
20. Arrildt KT, Joseph SB, Swanstrom R. The HIV-1 env protein: a coat of many colors. Curr HIV/AIDS Rep. 2012;9(1):52–63. doi:10.1007/s11904-011-0107-3. Informative review on compartmentalization from a virological point of view.
21. Joseph SB, Arrildt KT, Swanstrom AE, Schnell G, Lee B, Hoxie JA, et al. Quantification of entry phenotypes of macrophage-tropic HIV-1 across a wide range of CD4 densities. J Virol. 2014;88(4):1858–69. doi:10.1128/JVI. 02477-13.
22. Swanstrom R, Coffin J. HIV-1 pathogenesis: the virus. Cold Spring Harb Perspect Med. 2012;2(12):a007443. doi:10.1101/cshperspect.a007443.
23. del Saz SV, Sued O, Falco V, Aguero F, Crespo M, Pumarola T, et al. Acute meningoencephalitis due to human immunodeficiency virus type 1 infection in 13 patients: clinical description and follow-up. J Neurovirol. 2008;14(6):474–9. doi:10.1080/13550280802195367.
24. Schnell G, Spudich S, Harrington P, Price RW, Swanstrom R. Compartmentalized human immunodeficiency virus type 1 originates from long-lived cells in some subjects with HIV-1-associated dementia. PLoS Pathog. 2009;5(4):e1000395. doi:10.1371/journal.ppat.1000395.
25. Soulie C, Tubiana R, Simon A, Lambert-Niclot S, Malet I, Canestri A, et al. Presence of HIV-1 R5 viruses in cerebrospinal fluid even in patients harboring R5X4/X4 viruses in plasma. J Acquir Immune Defic Syndr. 2009;51(1):60–4. doi:10.1097/QAI.0b013e31819fb903.
26. Spudich SS, Huang W, Nilsson AC, Petropoulos CJ, Liegler TJ, Whitcomb JM, et al. HIV-1 chemokine coreceptor utilization in paired cerebrospinal fluid and plasma samples: a survey of subjects with viremia. J Infect Dis. 2005;191(6):890–8. doi:10.1086/428095.
27. Parisi SG, Andreoni C, Sarmati L, Boldrin C, Buonomini AR, Andreis S, et al. HIV coreceptor tropism in paired plasma, peripheral blood mononuclear cell, and cerebrospinal fluid isolates from antiretroviral-naive subjects. J Clin Microbiol. 2011;49(4):1441–5. doi:10.1128/JCM. 02564-10.
28. Albright AV, Shieh JT, Itoh T, Lee B, Pleasure D, O’Connor MJ, et al. Microglia express CCR5, CXCR4, and CCR3, but of these, CCR5 is the principal coreceptor for human immunodeficiency virus type 1 dementia isolates. J Virol. 1999;73(1):205–13.
29. Gorry PR, Bristol G, Zack JA, Ritola K, Swanstrom R, Birch CJ, et al. Macrophage tropism of human immunodeficiency virus type 1 isolates from brain and lymphoid tissues predicts neurotropism independent of coreceptor specificity. J Virol. 2001;75(21):10073–89. doi:10.1128/JVI. 75.21.10073-10089.2001.
30. Koenig S, Gendelman HE, Orenstein JM, Dal Canto MC, Pezeshkpour GH, Yungbluth M, et al. Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy. Science. 1986;233(4768):1089–93.
31. Gisslen M, Norkrans G, Svennerholm B, Hagberg L. The effect on human immunodeficiency virus type 1 RNA levels in cerebrospinal fluid after initiation of zidovudine or didanosine. J Infect Dis. 1997;175(2):434–7.
32. Spudich S, Lollo N, Liegler T, Deeks SG, Price RW. Treatment benefit on cerebrospinal fluid HIV-1 levels in the setting of systemic virological suppression and failure. J Infect Dis. 2006;194(12):1686–96. doi:10.1086/508750.
33. Robertson KR, Robertson WT, Ford S, Watson D, Fiscus S, Harp AG, et al. Highly active antiretroviral therapy improves neurocognitive functioning. J Acquir Immune Defic Syndr. 2004;36(1):562–6.
34. Haas DW, Johnson BW, Spearman P, Raffanti S, Nicotera J, Schmidt D, et al. Two phases of HIV RNA decay in CSF during initial days of multidrug therapy. Neurology. 2003;61(10):1391–6.
35. Ellis RJ, Gamst AC, Capparelli E, Spector SA, Hsia K, Wolfson T, et al. Cerebrospinal fluid HIV RNA originates from both local CNS and systemic sources. Neurology. 2000;54(4):927–36.
36. Churchill M, Nath A. Where does HIV hide? A focus on the central nervous system. Curr Opin HIV AIDS. 2013;8(3):165–9. doi:10.1097/COH.0b013e32835fc601.
37. Cinque P, Presi S, Bestetti A, Pierotti C, Racca S, Boeri E, et al. Effect of genotypic resistance on the virological response to highly active antiretroviral therapy in cerebrospinal fluid. AIDS Res Hum Retrovir. 2001;17(5):377–83. doi:10.1089/088922201750102409.
38. Dahl V, Peterson J, Fuchs D, Gisslen M, Palmer S, Price RW. Low levels of HIV-1 RNA detected in the cerebrospinal fluid after up to 10 years of suppressive therapy are associated with local immune activation. AIDS. 2014;28(15):2251–8. doi:10.1097/QAD.0000000000000400.
39. Letendre S, Marquie-Beck J, Capparelli E, Best B, Clifford D, Collier AC, et al. Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol. 2008;65(1):65–70. doi:10.1001/archneurol.2007.31.
40. Letendre SL, Ellis RJ, Ances BM, McCutchan JA. Neurologic complications of HIV disease and their treatment. Top HIV Med Publ Int AIDS Soc, USA. 2010;18(2):45–55.
41. Yilmaz A, Izadkhashti A, Price RW, Mallon PW, De Meulder M, Timmerman P, et al. Darunavir concentrations in cerebrospinal fluid and blood in HIV-1-infected individuals. AIDS Res Hum Retrovir. 2009;25(4):457–61. doi:10.1089/aid.2008.0216.
42. Croteau D, Rossi SS, Best BM, Capparelli E, Ellis RJ, Clifford DB, et al. Darunavir is predominantly unbound to protein in cerebrospinal fluid and concentrations exceed the wild-type HIV-1 median 90 % inhibitory concentration. J Antimicrob Chemother. 2013;68(3):684–9. doi:10.1093/jac/dks441.
43. Calcagno A, Yilmaz A, Cusato J, Simiele M, Bertucci R, Siccardi M, et al. Determinants of darunavir cerebrospinal fluid concentrations: impact of once-daily dosing and pharmacogenetics. AIDS. 2012;26(12):1529–33. doi:10.1097/QAD.0b013e3283553619.
44. Letendre SL, Mills AM, Tashima KT, Thomas DA, Min SS, Chen S, et al. ING116070: a study of the pharmacokinetics and antiviral activity of dolutegravir in cerebrospinal fluid in HIV-1-infected, antiretroviral therapy-naive subjects. Clin Infect Dis Off Publ Infect Dis Soc Am. 2014;59(7):1032–7. doi:10.1093/cid/ciu477.
45. Eden A, Fuchs D, Hagberg L, Nilsson S, Spudich S, Svennerholm B, et al. HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment. J Infect Dis. 2010;202(12):1819–25. doi:10.1086/657342. Shows the proportion of asymptomatic CSF viral escape in a group of ART-treated patients with suppressed systemic HIV replication. It also shows the association between CSF viral escape and intrathecal immune activation.
46. Edén A AL, Fuchs D, Hagberg L, Nilsson S, Svennerholm B, Yilmaz A, Zetterberg H, Gisslén M. Cerebrospinal fluid viral blips and persistent escape in HIV-infected patients on ART. Topics in antiviral medicine. 2014;22(2):(e–1):210.
47. Siliciano JD, Kajdas J, Finzi D, Quinn TC, Chadwick K, Margolick JB, et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med. 2003;9(6):727–8. doi:10.1038/nm880.
48. Imaz A, Cayuela N, Niubo J, Tiraboschi JM, Izquierdo C, Cabellos C, et al. Short communication: focal encephalitis related to viral escape and resistance emergence in cerebrospinal fluid in a patient on lopinavir/ritonavir monotherapy with plasma HIV-1 RNA suppression. AIDS Res Hum Retrovir. 2014;30(10):984–7. doi:10.1089/AID.2014.0014.
49. Gutmann C, Cusini A, Gunthard HF, Fux C, Hirschel B, Decosterd LA, et al. Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment and CD4-nadir. AIDS. 2010;24(15):2347–54. doi:10.1097/QAD.0b013e32833db9a1. Reports rebounds of HIV replication in CSF in association with neurological disease in patients failing a LPV/r monotherapy within a randomized clinical trial.
50. Bierhoff M, Boucher CA, Fibriani A, Ten Kate RW. Ongoing HIV replication in cerebrospinal fluid under successful monotherapy. Antivir Ther. 2013;18(4):641–3. doi:10.3851/IMP2530.
51. Mangioni D, Muscatello A, Sabbatini F, Soria A, Rossi M, Bisi L, et al. A case of cerebrospinal fluid viral escape on a dual antiretroviral regimen: worth the risk? Clin Infect Dis Off Publ Infect Dis Soc Am. 2014;59(11):1655–6. doi:10.1093/cid/ciu679.
52. Katlama C, Valantin MA, Algarte-Genin M, Duvivier C, Lambert-Niclot S, Girard PM, et al. Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136. AIDS. 2010;24(15):2365–74. doi:10.1097/QAD.0b013e32833dec20.
53. Vernazza P, Daneel S, Schiffer V, Decosterd L, Fierz W, Klimkait T, et al. The role of compartment penetration in PI-monotherapy: the Atazanavir-Ritonavir Monomaintenance (ATARITMO) Trial. AIDS. 2007;21(10):1309–15. doi:10.1097/QAD.0b013e32814e6b1c.
54. Santos JR, Munoz-Moreno JA, Molto J, Prats A, Curran A, Domingo P, et al. Virological efficacy in cerebrospinal fluid and neurocognitive status in patients with long-term monotherapy based on lopinavir/ritonavir: an exploratory study. PLoS ONE. 2013;8(7):e70201. doi:10.1371/journal.pone.0070201.
55. Estebanez M, Stella-Ascariz N, Mingorance J, Perez-Valero I, Gonzalez-Baeza A, Bayon C, et al. A comparative study of neurocognitively impaired patients receiving protease inhibitor monotherapy or triple-drug antiretroviral therapy. J Acquir Immune Defic Syndr. 2014;67(4):419–23. doi:10.1097/QAI.0000000000000337.
56. Ferretti F, Gianotti N, Lazzarin A, Cinque P. Central nervous system HIV infection in “less-drug regimen” antiretroviral therapy simplification strategies. Semin Neurol. 2014;34(1):78–88. doi:10.1055/s-0034-1372345.
57. Canestri A, Lescure FX, Jaureguiberry S, Moulignier A, Amiel C, Marcelin AG, et al. Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy. Clin Infect Dis Off Publ Infect Dis Soc Am. 2010;50(5):773–8. doi:10.1086/650538. The first published series of cases of symptomatic CSF viral escape.
58. Peluso MJ, Ferretti F, Peterson J, Lee E, Fuchs D, Boschini A, et al. Cerebrospinal fluid HIV escape associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled plasma viral load. AIDS. 2012;26(14):1765–74. doi:10.1097/QAD.0b013e328355e6b2. An additional detailed series of cases of symptomatic CSF viral escape.
59. Bingham R, Ahmed N, Rangi P, Johnson M, Tyrer M, Green J. HIV encephalitis despite suppressed viraemia: a case of compartmentalized viral escape. Int J STD AIDS. 2011;22(10):608–9. doi:10.1258/ijsa.2011.010507.
60. Bogoch II, Davis BT, Venna N. Reversible dementia in a patient with central nervous system escape of human immunodeficiency virus. J Infect. 2011;63(3):236–9. doi:10.1016/j.jinf.2011.05.011.
61. Khoury MN, Tan CS, Peaslee M, Koralnik IJ. CSF viral escape in a patient with HIV-associated neurocognitive disorder. J Neurovirol. 2013;19(4):402–5. doi:10.1007/s13365-013-0175-9.
62. Pasquet A, Ajana F, Melliez H, Giurca C, Poissy J, Yazdanpanah Y. Central nervous system HIV replication and HIV-related pachymeningitis in a patient on protease inhibitor monotherapy despite an undetectable plasma viral load. AIDS. 2012;26(13):1726–8. doi:10.1097/QAD.0b013e32835646fb.
63. Tamarit Mdel P, Quereda C, Gonzalez-Rozas M, Corral I, Casado JL. HIV type 1 viral encephalitis after development of viral resistance to plasma suppressive antiretroviral therapy. AIDS Res Hum Retrovir. 2012;28(1):83–6. doi:10.1089/AID.2011.0020.
64. van Lelyveld SF, Nijhuis M, Baatz F, Wilting I, van den Bergh WM, Kurowski M, et al. Therapy failure following selection of enfuvirtide-resistant HIV-1 in cerebrospinal fluid. Clin Infect Dis Off Publ Infect Dis Soc Am. 2010;50(3):387–90. doi:10.1086/649874.
65. Wendel KA, McArthur JC. Acute meningoencephalitis in chronic human immunodeficiency virus (HIV) infection: putative central nervous system escape of HIV replication. Clin Infect Dis Off Publ Infect Dis Soc Am. 2003;37(8):1107–11. doi:10.1086/378300.
66. Tucker KA, Robertson KR, Lin W, Smith JK, An H, Chen Y, et al. Neuroimaging in human immunodeficiency virus infection. J Neuroimmunol. 2004;157(1–2):153–62. doi:10.1016/j.jneuroim.2004.08.036.
67. Worthington MG, Ross JJ. Aseptic meningitis and acute HIV syndrome after interruption of antiretroviral therapy: implications for structured treatment interruptions. AIDS. 2003;17(14):2145–6. doi:10.1097/01.aids.0000088191.77946.3d.
68. Gray F, Lescure FX, Adle-Biassette H, Polivka M, Gallien S, Pialoux G, et al. Encephalitis with infiltration by CD8+ lymphocytes in HIV patients receiving combination antiretroviral treatment. Brain Pathol. 2013;23(5):525–33. doi:10.1111/bpa.12038. Detailed neuropathological description of cases with CD8+ cell encephalitis.
69. Lescure FX, Moulignier A, Savatovsky J, Amiel C, Carcelain G, Molina JM, et al. CD8 encephalitis in HIV-infected patients receiving cART: a treatable entity. Clin Infect Dis Off Publ Infect Dis Soc Am. 2013;57(1):101–8. doi:10.1093/cid/cit175.
70. Langford TD, Letendre SL, Marcotte TD, Ellis RJ, McCutchan JA, Grant I, et al. Severe, demyelinating leukoencephalopathy in AIDS patients on antiretroviral therapy. AIDS. 2002;16(7):1019–29. Detailed neuropathological description of HIV leukoencephalitis cases observed in the early ART era, mostly associated with systemic virological failure and characterized by brain inflammation.
71. de Almeida SM, Bhatt A, Riggs PK, Durelle J, Lazzaretto D, Marquie-Beck J, et al. Cerebrospinal fluid human immunodeficiency virus viral load in patients with neurosyphilis. J Neurovirol. 2010;16(1):6–12. doi:10.3109/13550280903514776.
72. Moling O, Rossi P, Rimenti G, Vedovelli C, Mian P. Varicella-zoster virus meningitis and cerebrospinal fluid HIV RNA. Scand J Infect Dis. 2001;33(5):398–9.
73. Falcone EL, Adegbulugbe AA, Sheikh V, Imamichi H, Dewar RL, Hammoud DA, et al. Cerebrospinal fluid HIV-1 compartmentalization in a patient with AIDS and acute varicella-zoster virus meningomyeloradiculitis. Clin Infect Dis Off Publ Infect Dis Soc Am. 2013;57(5):e135–42. doi:10.1093/cid/cit356.
74. Bremell D, Sall C, Gisslen M, Hagberg L. Lyme neuroborreliosis in HIV-1 positive men successfully treated with oral doxycycline: a case series and literature review. J Med Case Rep. 2011;5:465. doi:10.1186/1752-1947-5-465.